インタビュー
「Oral Presentation：婦人科癌に対する治療戦略」の座長 Robert L. Giuntoli氏に聞く
「婦人科癌に対する治療戦略」をテーマとしたOral Presentationでは，子宮頸癌や卵巣癌に対する化学療法の効果を検討した最新の研究が7演題報告された。これらの中にはLate breaking abstractが3演題含まれており，婦人科癌治療に携わる医師たちの大きな注目を集めた。
| 編集部 | 婦人科癌をはじめ癌の治療にあたっては高額な医療費が問題となっています。この問題についてどのようにお考えですか？ |
| Giuntoli氏 |  |
Get the Flash Player to see this player.
|
Download（クリックで保存） |
vaccine：ワクチン
HPV（human papilloma virus）：ヒトパピローマウイルス
dysplasia：異形成
cervical cancer：子宮頸癌
Economic issues tend to be a healthcare's limited resource. Now we have a limited number of dollars -- how should we expend those dollars？Typically, if we can find that good way of preventing cancer, that’s obviously the cheapest way. And one of the ways we’ve come up with doing that has been vaccine for HPV -- for human papilloma virus. That appears to significantly reduce the risk of dysplasia and from there we believe, reduce the risk of cervical cancer.
| 編集部 | 婦人科癌に対する最新の治療について教えてください。 |
| Giuntoli氏 | |
Get the Flash Player to see this player.
|
Download（クリックで保存） |
exotic：新種の
HER2（Human Epidermal Growth Factor Receptor Type2）：ヒト上皮増殖因子受容体
BRCA（breast cancer）：乳癌
ovarian cancer：卵巣癌
We are now looking at using more and more exotic treatment methods. Those exotic treatment methods are often more expensive however. And so it ends up coming down to how much improvement in survival do you get, versus how much money do you have to expend in order to be able to do that. At least in the session today we came over this HER2 inhibitor which really appears to give potential salvage options to patients with BRCA mutations and ovarian cancer.
| 編集部 | 本セッションでは日本のグループの発表もありましたが，どのような印象を持たれましたか？ |
| Giuntoli | |
Get the Flash Player to see this player.
|
Download（クリックで保存） |
gynecologic：婦人科の
dose-intense：投与量の強度
interact：相互作用のある
intraperitoneal chemotherapy：腹腔内化学療法
Yeah, there was a presentation by the Japanese gynecologic oncology group, today looking at the treatment of primary ovarian cancer with a traditional carboplatin taxol versus dose intense platinum taxol. And it showed potentially a survival benefit. So patients got the dose-intense taxol. And this would be a very interesting finding not only in and of itself but also it’s how that interacts, how that is important in intraperitoneal chemotherapy where we actually do give a weekly sort of presentation. So it’s very important, and very interesting, and very pleased to have the presentation today.
